后面这个倍力腾我觉得作为一个新的靶向药物还是非常值得期待的，因为从试验

The latter, as a new targeted drug, I think it is very worth looking forward to, because from the experimental evidence, it can indeed improve the renal response to lupus patients and reduce recurrence. These points are very good. As for whether it can achieve such an effect, because it is completely new and there is no experience of previous medicines, so this depends on the response of the patient to use it to confirm whether it can finally be used as a first-line treatment.

后面这个倍力腾我觉得作为一个新的靶向药物还是非常值得期待的，因为从试验证据来说确实能够对狼疮的病人提高肾脏的应答，而且减少复发，这几点都是非常好的，至于它是不是能够达到这样的效果，因为这是完全全新的，没有既往的药物借鉴的经验，所以这个也要看病人使用过的反应，才能证实它是不是最终能够作为一线治疗。

I think it is worth looking forward to the latter as a new targeted drug, because from the experimental evidence, it can improve the renal response of patients with lupus erythematosus, and reduce recurrence. These points are very good. As for whether it can achieve this effect, because it is completely new, and there is no previous drug reference experience, so this is very good It also depends on the patient's reaction to confirm whether it can eventually be used as a first-line treatment.<br>